Fast Market Research

Market Report, "Personalized Medicine in Oncology Partnering Terms and Agreements", Published

New Pharmaceuticals research report from Current Partnering is now available from Fast Market Research

 

Boston, MA -- (ReleaseWire) -- 01/22/2014 -- The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

View Full Report Details and Table of Contents

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of personalized medicine in oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine in oncology dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in personalized medicine in oncology partnering. The chapter also includes examples case studies of recent deals in personalized medicine in oncology partnering.

Chapter 3 provides a review of the leading personalized medicine in oncology deals since 2007. Deals are listed by headline value signed by all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of personalized medicine in oncology partnering deals signed and announced since January 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in personalized medicine in oncology partnering and dealmaking since 2007.

Companies Mentioned in this Report: Abbott Japan, Abbott Laboratories, Abraxis BioScience, ACADIA Pharmaceuticals, Acceleron Pharma, Achillion Pharmaceuticals, Adnexus Therapeutics, Adolor, AEterna Zentaris, Affymax, Agensys, Alfacell, Allergan, Ambit Biosciences, Amgen, Amylin Pharmaceuticals, Anacor Pharmaceuticals, Anesiva, Archemix, Ariad Pharmaceuticals, ArQule, Array Biopharma, ARYx Therapeutics, Astellas Pharma, AstraZeneca, Athersys, Atley Pharmaceuticals, Auriga Laboratories, Aventis, AVEO Pharmaceuticals, Barrier Therapeutics, Bayer, Biogen Idec, BioMarin Pharmaceuticals, BioMerieux, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, Cardiome Pharma, Celgene, Cell Genesys, Cepheid, ChemoCentryx, Cornerstone Biopharma, Cortex Pharmaceuticals, Critical Therapeutics, Cubist Pharmaceuticals, CV Therapeutics, Cypress Bioscience, Cytokinetics, Daiichi Sankyo, DepoMed, Dey Pharma, DoctorDirectory, DOR BioPharma, Dyax, Dynavax Technologies, Eisai, Eli Lilly, Enanta Pharmaceuticals, Endo Pharmaceuticals, Exelixis, Facet Biotechnology, Forest Laboratories, Forest Pharmaceuticals, Galderma, Genentech, Genzyme, Gilead Sciences, GlaxoSmithKline, GTx, Hyperion Therapeutics, ImmunoGen, Immunomedics, Impax Laboratories, Incyte, Inspire Pharmaceuticals, InterMune, InVentiv Health, Ipsen, Ironwood Pharmaceuticals, Janssen Research & Development, KaloBios Pharmaceuticals, La Jolla Pharmaceutical, Macrogenics, MAP Pharmaceuticals, Maxygen, Medivation, Menarini, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Merrimack Pharmaceuticals, Metabasis Therapeutics, Micromet, MiddleBrook Pharmaceutical, Millennium, Mylan Laboratories, Nektar Therapeutics, Novartis, Novartis Consumer Health, Novo Nordisk, Nycomed, OncoGenex Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Ortho Biotech, Par Pharmaceutical, PDL BioPharma, Pfizer, PhotoMedex, Procter & Gamble, Procter & Gamble Pharmaceuticals, Purdue Pharma, Regeneron Pharmaceuticals, Rib-X Pharmaceuticals, Roche, Sagent Pharmaceuticals, Salix Pharmaceuticals, Sanofi-Aventis, Sanofi-Pasteur, Sanofi, Santarus, Schering-Plough, Seattle Genetics, Serono, Sigma-Tau, Solvay, Somaxon Pharmaceuticals, Spectrum Pharmaceuticals, Strativa Pharmaceuticals, Sucampo Pharmaceuticals, Synta Pharmaceuticals, Takeda Pharmaceutical, TAP Pharmaceutical, Targacept, Tercica, Teva Pharmaceuticals, Tibotec, Transcept Pharmaceuticals, Ucyclyd Pharma, Valeant Pharmaceuticals, Veracyte, Vernalis, Vical, Victory Pharma, Warner Chilcott, Watson Pharmaceuticals, Wyeth, Xenoport, Zogenix, ZymoGenetics

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Personalized Medicine Partnering Terms and Agreements
- Oncology Partnering Terms and Agreements
- Regenerative medicine and Stem cells Partnering Terms and Agreements
- Cancer Vaccine Partnering Terms and Agreements
- Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Cancer Monoclonal Antibody Partnering Terms and Agreements
- Bioinformatics Partnering Terms and Agreements
- Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Cancer Diagnostics Partnering Terms and Agreements
- Infectious Vaccines Partnering Terms and Agreements